News for BioAtla, Inc. (BCAB)

On December 31, 2024, Millennium Management LLC executed a significant transaction involving BioAtla Inc. The firm reduced its holdings in the clinical-stage bi

BioAtla (BCAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

**media[497855]**

BioAtla announces $9.2 million stock and warrant sale

BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, Investor...

Research and Development Expenses: $16.4 million for Q3 2024, down from $28.4 million in Q3 2023.General and Administrative Expenses: $5.9 million for Q3 2024,

Nov 07, 2024 / 09:30PM GMTOperator Good day, everyone and welcome to today's Bioatla third-quarter, 2024 earnings call. (Operator Instructions) It is now my ple

We recently compiled a list of the Michael Burry's Top 10 Stock Picks Heading into 2025. In this article, we are going to take a look at where BioAtla, Inc.

Established in May 2013, Scion Asset Management is a renowned and well-regarded California-based hedge fund founded by Michael Burry.

One of the best resources for investors are the publicly available 13F-HR documents that each fund is required to submit to the SEC. These documents allow inves...

Texas-based Beneficient (BENF), a technology-enabled financial services company is up over 55 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

BeyondSpring Inc. (BYSI) experienced a notable stock price increase of 5.39%, reaching $2.54 per share. The trading volume was 20,920 shares, with a turnover ra

Nanomedicine is experiencing heightened demand, mainly propelled by the increasing occurrence of chronic ailments like cardiovascular, neurological,...

The demand for biopharmaceuticals is primarily driven by the increasing prevalence of chronic, infectious, and neurological diseases, coupled with the...

The dynamics of the osteosarcoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising...

The interest of Pharma and the research community in AXL inhibitors as anticancer agents has dramatically increased over the past years. The growing number...

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.56%

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

As per DelveInsight, recent advances in Cervical Cancer have provided new options for treating patients with advanced forms of the disease, fulfilling a...